Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis

dc.contributor.authorZrubka, Zsombor
dc.contributor.authorGulácsi, László
dc.contributor.authorBrodszky, Valentin
dc.contributor.authorRencz, Fanni
dc.contributor.authorAlten, Rieke
dc.contributor.authorSzekanecz, Zoltán
dc.contributor.authorPéntek, Márta
dc.date.accessioned2019-10-25T09:54:26Z
dc.date.available2019-10-25T09:54:26Z
dc.date.issued2019
dc.date.oa2019-10-28
dc.date.pasync2020-02-27T01:30:22Z
dc.date.updated2020-02-27T01:30:22Z
dc.description.correctorLB
dc.identifier.citationExpert Review of Pharmacoeconomics & Outcomes Research. -19 : 5 (2019), p. 537-549. -Expert Review of Pharmacoeconomics & Outcomes Research. - 1473-7167. - 1744-8379
dc.identifier.doihttp://dx.doi.org/10.1080/14737167.2019.1647104
dc.identifier.issn1473-7167
dc.identifier.issn1744-8379
dc.identifier.opachttp://webpac.lib.unideb.hu:8082/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM081584
dc.identifier.urihttp://hdl.handle.net/2437/275040
dc.identifier.urlhttps://www.tandfonline.com/doi/full/10.1080/14737167.2019.1647104
dc.languageeng
dc.rights.accessopen access article
dc.subject.mabOrvostudományok
dc.subject.mabKlinikai orvostudományok
dc.titleLong-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis
dc.typeidegen nyelvű folyóiratközlemény külföldi lapban
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
FILE_UP_1_428 Zrubka SzZ Gulácsi infliximab costeff Expert Rev Pharmacoecon Outcome Res 2019.pdf
Méret:
2.36 MB
Formátum:
Adobe Portable Document Format
Leírás:
kiadói változat